Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Autor:	Cazzaniga G; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy gianni.cazzaniga@hsgerardo.org., De Lorenzo P; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy.; European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy., Alten J; Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland., Röttgers S; Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland., Hancock J; Children's Cancer and Leukaemia Group (CCLG), UK., Saha V; Children's Cancer and Leukaemia Group (CCLG), UK., Castor A; Nordic Society of Paediatric Haematology and Oncology (NOPHO), Sweden, Denmark, Norway, Finland and Iceland., Madsen HO; Nordic Society of Paediatric Haematology and Oncology (NOPHO), Sweden, Denmark, Norway, Finland and Iceland., Gandemer V; French Acute Lymphoblastic Leukemia Study Groups (French Acute Lymphoblastic Leukemia Study Group, FRALLE and European Organisation for Research and Treatment of Cancer, EORTC), Italy., Cavé H; French Acute Lymphoblastic Leukemia Study Groups (French Acute Lymphoblastic Leukemia Study Group, FRALLE and European Organisation for Research and Treatment of Cancer, EORTC), Italy., Leoni V; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy., Köhler R; Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland., Ferrari GM; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy., Bleckmann K; Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland., Pieters R; Dutch Childhood Oncology Group (DCOG), the Netherlands., van der Velden V; Dutch Childhood Oncology Group (DCOG), the Netherlands., Stary J; Czech Pediatric Hematology Working Group (CPH), Czech Republic., Zuna J; Czech Pediatric Hematology Working Group (CPH), Czech Republic., Escherich G; Cooperative study group for treatment of ALL (COALL), Germany., Stadt UZ; Cooperative study group for treatment of ALL (COALL), Germany., Aricò M; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Azienda Sanitaria Provinciale, Ragusa, Italy., Conter V; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy., Schrappe M; Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland., Valsecchi MG; European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy., Biondi A; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy.; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
Jazyk:	angličtina
Zdroj:	Haematologica [Haematologica] 2018 Jan; Vol. 103 (1), pp. 107-115. Date of Electronic Publication: 2017 Oct 27.
DOI:	10.3324/haematol.2017.176917
Abstrakt:	The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged immunoglobulin/T-cell receptor genes (IG/TR) and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving Berlin-Frankfurt-Münster (BFM) high-risk (HR) therapy and post-induction intermittent imatinib (the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) study). MRD was monitored after induction (time point (TP)1), consolidation Phase IB (TP2), HR Blocks, reinductions, and at the end of therapy. MRD negativity progressively increased over time, both by IG/TR and BCR/ABL1. Of 90 patients with IG/TR MRD at TP1, nine were negative and none relapsed, while 11 with MRD<5×10 -4 and 70 with MRD≥5×10 -4 had a comparable 5-year cumulative incidence of relapse of 36.4 (15.4) and 35.2 (5.9), respectively. Patients who achieved MRD negativity at TP2 had a low relapse risk (5-yr cumulative incidence of relapse (CIR)=14.3[9.8]), whereas those who attained MRD negativity at a later date showed higher CIR, comparable to patients with positive MRD at any level. BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses). The overall concordance between the two methods is 69%, with significantly higher positivity by BCR/ABL1. In conclusion, MRD monitoring by both methods may be functional not only for measuring response but also for guiding biological studies aimed at investigating causes for discrepancies, although from our data IG/TR MRD monitoring appears to be more reliable. Early MRD negativity is highly predictive of favorable outcome. The earlier MRD negativity is achieved, the better the prognosis. (Copyright© 2018 Ferrata Storti Foundation.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu